Advertisement
Advertisement
U.S. markets open in 9 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

AMRN Jan 2023 3.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.06000.0000 (0.00%)
As of 11:05AM EDT. Market open.
Advertisement
Full screen
Previous Close0.0600
Open0.0600
Bid0.0500
Ask0.1500
Strike3.00
Expire Date2023-01-20
Day's Range0.0600 - 0.0600
Contract RangeN/A
Volume20
Open Interest4.28k
  • GlobeNewswire

    Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference

    DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. H.C. Wainwright 24th Annual Global Investment Conference (September 12-14th, 2022; New York, New York) Date/Time: September 12, 2022, 9:00 a.m. ET/ 1:00 p.m. GMT+1 Webcast: https://journey.ct

  • Benzinga

    Amarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers

    Amarin Corporation plc (NASDAQ: AMRN) announced that new REDUCE-IT data show that Vascepa/Vazkepa (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. In this post hoc exploratory analysis, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total primary composite events in current/former smokers by 23% and in former smokers by 29%, compared to the placebo. Related: Amarin's New Vascepa Data Shows Significant Reduction

  • GlobeNewswire

    New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

    -- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis -- -- Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular Pharmacotherapy -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 28, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new RED

Advertisement
Advertisement